Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 02/23/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Global X China Biotech Innovation ETF

CHB | ETF

$6.64

$2.05 M

0.11%

$0.01

0.65%

Vitals

YTD Return

-18.0%

1 yr return

-30.3%

3 Yr Avg Return

-26.9%

5 Yr Avg Return

N/A

Net Assets

$2.05 M

Holdings in Top 10

61.0%

52 WEEK LOW AND HIGH

$6.6
$6.64
$10.04

Expenses

OPERATING FEES

Expense Ratio 0.65%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover N/A

Redemption Fee N/A

Min Investment

Standard (Taxable)

N/A

IRA

N/A

Fund Classification

Fund Type

Exchange Traded Fund

Name

As of 02/23/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Global X China Biotech Innovation ETF

CHB | ETF

$6.64

$2.05 M

0.11%

$0.01

0.65%

CHB - Profile

Distributions

  • YTD Total Return -18.0%
  • 3 Yr Annualized Total Return -26.9%
  • 5 Yr Annualized Total Return N/A
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.31%
DIVIDENDS
  • Dividend Yield 0.1%
  • Dividend Distribution Frequency SemiAnnual

Fund Details

  • Legal Name
    Global X China Biotech Innovation ETF
  • Fund Family Name
    Global X Funds
  • Inception Date
    Sep 22, 2020
  • Shares Outstanding
    270100
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Nam To

Fund Description

The Fund invests at least 80% of its total assets, plus borrowings for investment purposes (if any), in the securities of the Solactive China Biotech Innovation Index ("Underlying Index") and in American Depositary Receipts ("ADRs") and Global Depositary Receipts ("GDRs") based on the securities in the Underlying Index. The Fund's 80% investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed.
The Underlying Index is designed to provide exposure to exchange-listed companies that are directly involved in China’s biotechnology industry. The securities eligible for inclusion in the Underlying Index include:
•H-Shares (securities of companies incorporated in China that are denominated in Hong Kong Dollars and listed on the Hong Kong Stock Exchange (the "HKSE"));
•Red Chips (securities of companies with a majority of their business operations in mainland China and that are controlled by the national government or local governments of China, traded on the HKSE in Hong Kong dollars);
•P-Chips (securities of companies with the majority of their business operations in mainland China and controlled by individuals in China, but that are incorporated outside of China);
•A-Shares (securities of companies incorporated in mainland China that trade on Chinese exchanges in renminbi) that are accessible through the Shanghai-Hong Kong Stock Connect program ("Shanghai Connect") or the Shenzhen-Hong Kong Stock Connect program ("Shenzhen Connect", and together with Shanghai Connect, "Stock Connect Programs"); and
•Foreign listings such as American Depository Receipts ("ADRs").
The Stock Connect Programs are securities trading and clearing programs that aim to achieve mutual stock market access between China and Hong Kong. Under the Stock Connect Programs, the Fund's trading of eligible A-Shares listed on the Shanghai Stock Exchange ("SSE") or Shenzhen Stock Exchange ("SZSE"), as applicable, would be effectuated through its Hong Kong brokers. Trading through the Stock Connect Programs is subject to a daily quota, which limits the maximum net purchases under Stock Connect Programs each day, and as such, buy orders for A-Shares would be rejected once the daily quota is exceeded (although the Fund will be permitted to sell A-Shares regardless of the daily quota balance). The daily quota is not specific to the Fund. From time to time, other stock exchanges in China may participate in Stock Connect Programs, and A-Shares listed and traded on such other stock exchanges and accessible through Stock Connect Programs may be added to the Underlying Index, as determined by Solactive AG, the provider of the Underlying Index (the “Index Provider”).
In constructing the Underlying Index, the Index Provider utilizes FactSet Industry classifications to identify companies that are directly involved in the biotechnology industry. Only those securities classified in the biotechnology industry according to FactSet as of each rebalance date are eligible for inclusion in the Underlying Index.
To be a part of the eligible universe of the Underlying Index, certain minimum market capitalization and liquidity criteria, as defined by the Index Provider, must be met. As of January 31, 2023, companies must have a minimum free float market capitalization of $200 million and a minimum average daily turnover for the last 6 months greater than or equal to $2 million in order to be eligible for inclusion in the Underlying Index.
The Underlying Index is weighted according to a modified capitalization weighting methodology and is reconstituted and re-weighted semi-annually. Modified capitalization weighting seeks to weight constituents primarily based on market capitalization, but subject to caps on the weights of the individual securities. During each rebalance, the maximum weight of a company is capped at 8%, the aggregate weight of companies with a weight greater than or equal to 5% is capped at 40%, all remaining companies are capped at a weight of 4.5%, and all constituents are subject to a minimum weight of 0.3%. Generally speaking, this approach will limit the amount of concentration in the largest market capitalization companies and increase company-level diversification. The Underlying Index may include large-, mid- or small-capitalization companies, and components primarily include health care companies. As of January 31, 2023, the Underlying Index had 26 constituents. The Fund's investment objective and Underlying Index may be changed without shareholder approval.
The Underlying Index is sponsored by the Index Provider, which is an organization that is independent of, and unaffiliated with, the Fund and Global X Management Company LLC, the investment adviser for the Fund ("Adviser"). The Index Provider determines the relative weightings of the securities in the Underlying Index and publishes information regarding the market value of the Underlying Index.
The Adviser uses a "passive" or indexing approach to try to achieve the Fund's investment objective. Unlike many investment companies, the Fund does not try to outperform the Underlying Index and does not seek temporary defensive positions when markets decline or appear overvalued.
The Fund generally will use a replication strategy. A replication strategy is an indexing strategy that involves investing in the securities of the Underlying Index in approximately the same proportions as in the Underlying Index. However, the Fund may utilize a representative sampling strategy with respect to the Underlying Index when a replication strategy might be detrimental or disadvantageous to shareholders, such as when there are practical difficulties or substantial costs involved in compiling a portfolio of equity securities to replicate the Underlying Index, in instances in which a security in the Underlying Index becomes temporarily illiquid, unavailable or less liquid, or as a result of legal restrictions or limitations (such as tax diversification requirements) that apply to the Fund but not the Underlying Index.
The Adviser expects that, over time, the correlation between the Fund's performance and that of the Underlying Index, before fees and expenses, will exceed 95%. A correlation percentage of 100% would indicate perfect correlation. If the Fund uses a replication strategy, it can be expected to have greater correlation to the Underlying Index than if it uses a representative sampling strategy.
The Fund concentrates its investments (i.e., holds 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated. As of January 31, 2023, the Underlying Index was concentrated in the Underlying Index was concentrated in the biotechnology industry and had significant exposure to the health care sector.
Read More

CHB - Performance

Return Ranking - Trailing

Period CHB Return Category Return Low Category Return High Rank in Category (%)
YTD -18.0% -18.0% 4.5% 100.00%
1 Yr -30.3% -33.8% 19.6% 95.15%
3 Yr -26.9%* -32.0% 2.9% 84.04%
5 Yr N/A* -15.8% 14.4% 35.48%
10 Yr N/A* -4.6% 9.2% 66.67%

* Annualized

Return Ranking - Calendar

Period CHB Return Category Return Low Category Return High Rank in Category (%)
2023 -14.0% -26.6% 26.3% 24.27%
2022 -33.4% -41.6% -9.4% 90.63%
2021 -13.5% -52.5% 26.5% 40.86%
2020 N/A 1.3% 138.5% N/A
2019 N/A -1.9% 42.6% N/A

Total Return Ranking - Trailing

Period CHB Return Category Return Low Category Return High Rank in Category (%)
YTD -18.0% -18.0% 4.5% 100.00%
1 Yr -30.3% -33.8% 19.6% 95.15%
3 Yr -26.9%* -32.0% 2.9% 84.04%
5 Yr N/A* -15.8% 14.4% N/A
10 Yr N/A* -4.6% 9.2% N/A

* Annualized

Total Return Ranking - Calendar

Period CHB Return Category Return Low Category Return High Rank in Category (%)
2023 -13.6% -25.7% 30.1% 37.86%
2022 -33.3% -40.4% -6.8% 94.79%
2021 -13.5% -48.9% 29.5% 59.14%
2020 N/A 2.0% 138.5% N/A
2019 N/A 7.8% 44.4% N/A

CHB - Holdings

Concentration Analysis

CHB Category Low Category High CHB % Rank
Net Assets 2.05 M 1.13 M 6.93 B 96.12%
Number of Holdings 44 26 1189 77.00%
Net Assets in Top 10 1.4 M 534 K 3.45 B 91.00%
Weighting of Top 10 61.01% 0.4% 81.8% 6.00%

Top 10 Holdings

  1. CHONGQING ZHIFEI BIOLOGICA-A COMMON STOCK 8.53%
  2. CSPC PHARMACEUTICAL GROUP LT COMMON STOCK 8.34%
  3. CHANGCHUN HIGH NEW TECH-A COMMON STOCK 8.31%
  4. WUXI BIOLOGICS CAYMAN INC COMMON STOCK 6.75%
  5. WALVAX BIOTECHNOLOGY CO-A COMMON STOCK 6.26%
  6. BEIJING TIANTAN BIOLOGICAL-A COMMON STOCK 4.92%
  7. SHANGHAI RAAS BLOOD PRODUC-A COMMON STOCK 4.91%
  8. SICHUAN KELUN PHARMACEUTIC-A COMMON STOCK 4.51%
  9. HUALAN BIOLOGICAL ENGINEER-A COMMON STOCK 4.32%
  10. GENSCRIPT BIOTECH CORP COMMON STOCK 4.17%

Asset Allocation

Weighting Return Low Return High CHB % Rank
Stocks 		99.96% 0.00% 101.98% 10.89%
Cash 		0.04% 0.00% 99.01% 95.00%
Preferred Stocks 		0.00% 0.00% 2.60% 86.00%
Other 		0.00% -0.02% 47.32% 80.00%
Convertible Bonds 		0.00% 0.00% 0.15% 85.86%
Bonds 		0.00% 0.00% 69.90% 86.14%

Stock Sector Breakdown

Weighting Return Low Return High CHB % Rank
Healthcare 		95.49% 0.00% 100.00% 2.02%
Consumer Defense 		4.51% 0.00% 20.13% 79.80%
Utilities 		0.00% 0.00% 11.37% 91.92%
Technology 		0.00% 0.00% 58.02% 100.00%
Real Estate 		0.00% 0.00% 22.12% 95.96%
Industrials 		0.00% 0.00% 36.69% 100.00%
Financial Services 		0.00% 0.00% 41.62% 100.00%
Energy 		0.00% 0.00% 19.38% 90.91%
Communication Services 		0.00% 0.00% 41.06% 97.98%
Consumer Cyclical 		0.00% 0.00% 95.37% 100.00%
Basic Materials 		0.00% 0.00% 19.86% 97.98%

Stock Geographic Breakdown

Weighting Return Low Return High CHB % Rank
Non US 		96.21% 0.00% 99.76% 24.00%
US 		3.76% 0.00% 99.93% 59.00%

CHB - Expenses

Operational Fees

CHB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.65% 0.09% 12.20% 88.00%
Management Fee 0.65% 0.09% 1.50% 17.48%
12b-1 Fee N/A 0.00% 1.00% 48.28%
Administrative Fee N/A 0.06% 0.25% N/A

Sales Fees

CHB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

CHB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 2.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

CHB Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover N/A 4.00% 241.00% N/A

CHB - Distributions

Dividend Yield Analysis

CHB Category Low Category High CHB % Rank
Dividend Yield 0.11% 0.00% 5.64% 24.27%

Dividend Distribution Analysis

CHB Category Low Category High Category Mod
Dividend Distribution Frequency SemiAnnual Annual Annual Annual

Net Income Ratio Analysis

CHB Category Low Category High CHB % Rank
Net Income Ratio -0.31% -1.76% 3.66% 70.71%

Capital Gain Distribution Analysis

CHB Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Semi-Annually Annually

Distributions History

View More +

CHB - Fund Manager Analysis

Managers

Nam To

Start Date

Tenure

Tenure Rank

Sep 22, 2020

1.69

1.7%

Nam To, CFA, joined Global X Management Company LLC in July 2017 as a Portfolio Management Analyst. Mr. To has been a Portfolio Manager of the Fund since March 1, 2018. Previously, Mr. To was a Global Economics Research Analyst at Bunge Limited from 2014 through 2017 and an Advisory and Investment Analyst at Horizon Capital Group from June 2013 through August 2013. Mr. To received his Bachelor of Arts in Philosophy and Economics from Cornell University in 2014.

Wayne Xie

Start Date

Tenure

Tenure Rank

Sep 22, 2020

1.69

1.7%

Wayne Xie joined the Global X Management Company LLC in July 2018 as a Portfolio Management Associate. Previously, Mr. Xie was an Analyst at VanEck Associates on the Equity ETF Investment Management team from 2010 to 2018 and a Portfolio Administrator at VanEck Associates from 2007 to 2010. Mr. Xie received his BS in Business Administration from State University of New York at Buffalo.

Kimberly Chan

Start Date

Tenure

Tenure Rank

Sep 22, 2020

1.69

1.7%

Kimberly Chan is a Portfolio Management Associate. Previously, Ms. Chan was a US Associate Trader at Credit Agricole from 2016 to 2018, and an Investment Analyst at MetLife Investments from 2015 to 2016. Ms. Chan received her Bachelor of Science from New York University in 2015.

Vanessa Yang

Start Date

Tenure

Tenure Rank

Dec 31, 2020

1.41

1.4%

Vanessa Yang, Portfolio Management Associate, joined Global X Management Company LLC in 2016 as a Portfolio Administrator. She was appointed to the portfolio management team in June 2019. Previously, Ms. Yang was a Portfolio Administrator at VanEck Associates from 2011 to 2014. Ms. Yang received her MS in Financial Engineering from Drucker School of Management in 2010 and her BS in Economics from Guangdong University of Foreign Studies in 2008.

William Helm

Start Date

Tenure

Tenure Rank

Apr 01, 2022

0.16

0.2%

William Helm, CFA, Portfolio Manager, joined the Adviser in September 2021. Previously, Mr. Helm spent 14 years at Vanguard where he most recently served as an Equity Portfolio Manager and Trader. Previously, he held roles in Portfolio Review, Corporate Strategy and Corporate Finance. Mr. Helm received his BBA in Economics from Belmont University in 2007 and his MBA from Columbia Business School in 2020.

Sandy Lu

Start Date

Tenure

Tenure Rank

Apr 01, 2022

0.16

0.2%

Sandy Lu, CFA, Portfolio Manager, joined the Adviser in September 2021. Previously, Mr. Lu worked at PGIM Fixed Income from 2014 to 2021, where he led the portfolio analyst team covering Emerging Markets Debt. He began his career in 2010 as an Investment Analyst at Lincoln Financial Group. Mr. Lu graduated with a B.S. in Economics from the Wharton School of the University of Pennsylvania. He earned his CFA designation in September 2015, and holds the Series 3 license.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.09 24.1 3.67 3.22

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.